Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cosentyx
Pharma
Novartis stares down $16.7B post-2030 patent cliff
Three of Novartis’ largest current growth pillars are projected to plunge from $23.9 billion in sales in 2030 to just $7.2 billion in 2035.
Angus Liu
Nov 19, 2026 11:45am
Novartis buffers price erosion with Cosentyx's 11th FDA nod
Nov 17, 2026 2:00pm
Newer drugs came to Novartis' aid as top-selling brands stalled
Oct 28, 2025 11:18am
Novartis, Boehringer debut DTC programs with reduced drug prices
Sep 29, 2025 12:06pm
Novartis' Pluvicto picks up speed, delivers another trial win
Jul 17, 2025 10:56am
Novartis increases sales growth estimate through 2029
Nov 21, 2024 11:57am